-
Blood: Targeting GCK Paths . . . A new option for treating RAS mutant MM.
Time of Update: 2020-10-19
these effects are saved by expressing a shRNA resistance GCK, thus eliminating the potential non-target effects of GCK gene knock-out.
GCK inhibitor TL4-12 can reduce the expression of IKZF1 and BCL-6, inhibit MM cell proliferation and induce apoptosis.
-
Lancet oncol: EZH2 inhibitor, promising to be a new option for patients with folytic lymphoma!
Time of Update: 2020-10-19
July 9, 2015 - May 24, 2019, 99 patients were recruited: 45 EZH2 mutants and 54 EZH2 wild.
adverse reactions associated with severe treatment were found in 4 patients (4%).
-
HALPRYZA, Xinda Bio's lyxid anti-injection fluid, was approved by NMPA for the treatment of malignant lymphoma.
Time of Update: 2020-10-19
Cynda Bio announced that its recombinant human/rat-embedded monoclonal antibody HALPRYZA (Lytoxi monoantigen injection) developed with Lilly has been officially approved by the State Drug Administration of China (NMPA) for the treatment of diffuse large B-cell lymphoma (DLBCL), filthy lymphoma (FL) and chronic lymphocytic leukemia (CLL).
-
Blood: PaX5 mutation in the embryo line of familial B-cell premeditation-acute lymphoblastic leukemia.
Time of Update: 2020-10-19
In recent years, through genome-wide sequencing analysis, there has been a great deal of convincing evidence that the role of genetic susceptivity in children's B-cell prelub-acute lymphoblastic leukemia (BCP-ALL) is caused by the PAX5 gene mutation.
-
Blood: CLL's high-order immunoglobulin genealogy limitations: stereotyped subsypes s2 #169.
Time of Update: 2020-10-19
Particularly noteworthy is the prevalence of an SHM in the link region between the variable and conservative domains of the IGLV3-21 light chain, which has been reported in previous studies as critical to IG-like interactions based on cellular auto-signaling capabilities.
-
Two new drugs targeted at apoptosis have been designated by the FDA for orphan drugs.
Time of Update: 2020-10-19
Ascentage Pharma has announced that the U.S. Food and Drug Administration (FDA) has awarded two of its death inhibitors the "Orphan Drug Title (ODD)." one inhibitor, MDM2-p53, APG-115, is used to treat acute myeloid leukemia (AML) and the other is Bcl-2/Bcl-xL inhibitor APG-1252 for the treatment of small cell lung cancer (SCLC).
-
A doctor was treating a heart patient at the time of the hospital's crash.
Time of Update: 2020-10-17
Hospital: At the time of the incident, doctors were rescuing heart patients the hospital responded, "Because of the outbreak and during the holidays, security nurses are a person eyeing a post, but also ask the parties to understand." October 10 at 10 a.m., Jilin University Sino-Japanese Friendship Hospital staff to the Health Times reporter, according to surveillance video, etc.
-
It specializes in "biting" human bones! People with low back pain should be careful of this blood tumor.
Time of Update: 2020-10-13
Back pain seems to have become the common disease of modern people regardless of men, women and children, young and middle-aged or old people are more or less present in these conditions some people m
-
Am J Hematol: Conditioning therapy prior to hematopoietic stem cell transplantation.
Time of Update: 2020-10-13
, 16 patients received transplants from relative donors.
all but one patient who died prematurely had a neutral granulocyte transplant at 19 days in the mid-stage.
but the rate of chronic GVHD is relatively high and needs further improvement.
-
Blood: The activity of the VIII factor produced by genetically modified in human plasma after AAV5 gene therapy.
Time of Update: 2020-10-13
further experiments in two subjects showed that FVIII-SQ produced by GM accelerated the formation of early factors Xa and clotting enzymes, which may explain the higher OS activity based on the dynamic deviation between OS and CS detection read time.
-
Blood: Pym single antisequential AVD chemotherapy is effective in treating classic Hodgkin's lymphoma.
Time of Update: 2020-10-13
two patients with large lumps received CMR after two AVD cycles and maintained their remission at the end of treatment with tumor volume changes (A→B, C→D) after three courses of Pym monotherapy.
-
Blood: A high-order link between stereotyped subsypes of chronic lymphocytic leukemia.
Time of Update: 2020-10-13
The clinical characteristics of the rigid subtype and its satellite subsets are consistent, and these results confirm the previous view of Andreas and others that the main subtypes can be well identified and consistent in relative proportion, and therefore represent different disease variants, suitable for zoning studies, and have the potential to overcome the obvious heterogeneity of CLL.
-
The stomach is getting bigger and bigger, the girl who loves Korean drama has the "main woman's disease"?! Experts say leukemia is not all terminal!
Time of Update: 2020-10-13
Jie, director of the hematology department at Zhejiang University Hospital, said: In my one-and-a-half-day clinic, about 50 patients were received, and slow-grain patients accounted for about 10%." " after 3 weeks of treatment, the blood indicators of the swelling basically returned to normal, the swollen spleen is gradually smaller.
-
Biol Blood Marrow Transplant: Heterogenetic stem cell transplantation provides long-lasting relief for patients with primary B-cell lymphoma.
Time of Update: 2020-10-13
summary, in our multi-center retrospective study, alloHSCT produced lasting relief in some patients treating sensitive diseases before transplantation (44 percent for 5 years PFS) and should be considered in the treatment of patients with reel/ref PMBCL.
-
Clin Cancer Res: Effects of acute and chronic graft resistance to MDS on long-term prognosis after hematogenes transplantation.
Time of Update: 2020-10-13
multivariable analysis showed that in patients with low-risk MDS, the grade or severity of acute and chronic GVHD had no significant effect on total mortality, recurrence rate, or non-mortality (NRM).
-
Blood: The contribution of Vav1 mutations in the occurrence of mature T-cell tumors.
Time of Update: 2020-10-13
total transcription group analysis (WTA) showed that p53-/-Vav1-TG mice had multiple Myc-related path-riches in TCN compared to p53-/- or wild T-cells.
, JQ1, a bromine domain inhibitor targeted by the Myc path, treated naked mice transplanted with p53-/-Vav1-TG tumor cells, extending the survival time of mice.
-
IMGN632 Treats Recurring Recurring Cystic Plasma Cell-like Syndicular Cell Tumors: FDA Awards Breakthrough Therapy.
Time of Update: 2020-10-13
Biopharmaceutical company ImmunoGen recently announced that its antibody-drug compound (ADCs) IMGN632 has been awarded a "breakthrough therapy title" by the U.S. Food and Drug Administration (FDA) for the treatment of recurring or recurring recurring reoccurring reoccurring cystic plasma cell-like dendrites (BPDCN).
-
Blood Adv: Vido bead monoantigene can prevent isogenetic hematopoietic stem cell transplantation after transplant anti-host disease.
Time of Update: 2020-10-13
results, IV vedolizumab was given on the first, 13th, and 42nd days of alllo-HSCT, starting at 75 mg, with dose upgrades under the guidance of tolerance and pharmacodynamics.
participants in the 75-mg queue showed improvedGlucksberg II to IV aGVHD 100 days after alllo-HSCT.
-
Clin Cancer Res: The effect of MYC rearm on prognosis in patients with multiple myeloma.
Time of Update: 2020-10-12
study was designed to assess the effects of MYC rearm on the clinical characteristics, treatment response and survival rates of newly diagnosed MMs.
-
APL-106 Treatment of Acute Myeloid Leukemia: Phase III Briddle Study will be initiated.
Time of Update: 2020-10-12
Biopharmaceutical company Apollomic announced today that APL-106 (uproleselan) has been approved by china's National Drug Administration (NMPA) Drug Review Center (CDE) to conduct a Phase III briditation study of APL-106 (uproleselan) in combination with chemotherapy to treat recurrence/difficult acute myeloid leukemia (AML).
